114 related articles for article (PubMed ID: 22939966)
1. Characterisation of high dose aerosols from dry powder inhalers.
Grasmeijer F; Hagedoorn P; Frijlink HW; de Boer AH
Int J Pharm; 2012 Nov; 437(1-2):242-9. PubMed ID: 22939966
[TBL] [Abstract][Full Text] [Related]
2. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
[TBL] [Abstract][Full Text] [Related]
3. Reducing bounce effects in the Andersen cascade impactor.
Dunbar C; Kataya A; Tiangbe T
Int J Pharm; 2005 Sep; 301(1-2):25-32. PubMed ID: 16023806
[TBL] [Abstract][Full Text] [Related]
4. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations.
Pilcer G; Vanderbist F; Amighi K
Int J Pharm; 2008 Jun; 358(1-2):75-81. PubMed ID: 18359587
[TBL] [Abstract][Full Text] [Related]
5. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems.
Wong W; Fletcher DF; Traini D; Chan HK; Crapper J; Young PM
J Pharm Sci; 2011 Jul; 100(7):2744-54. PubMed ID: 21360707
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Abbreviated Impactor Measurements (AIM) and Efficient Data Analysis (EDA) for Dry Powder Inhalers (DPIs) Against the Full-Resolution Next Generation Impactor (NGI).
Mohan M; Lee S; Guo C; Peri SP; Doub WH
AAPS PharmSciTech; 2017 Jul; 18(5):1585-1594. PubMed ID: 27624069
[TBL] [Abstract][Full Text] [Related]
7. Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines.
Wong W; Crapper J; Chan HK; Traini D; Young PM
J Pharm Biomed Anal; 2010 Mar; 51(4):853-7. PubMed ID: 19932579
[TBL] [Abstract][Full Text] [Related]
8. Cascade impactor practice for a high dose dry powder inhaler at 90 L/min: NGI versus modified 6-stage and 8-stage ACI.
Kamiya A; Sakagami M; Byron PR
J Pharm Sci; 2009 Mar; 98(3):1028-39. PubMed ID: 18661538
[TBL] [Abstract][Full Text] [Related]
9. Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors.
Taki M; Marriott C; Zeng XM; Martin GP
Int J Pharm; 2010 Mar; 388(1-2):40-51. PubMed ID: 20026261
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of solution-based pressurised metered-dose inhaler aerosols with an optical particle counter.
Kuhli M; Weiss M; Steckel H
Eur J Pharm Biopharm; 2010 Aug; 75(3):393-8. PubMed ID: 20347974
[TBL] [Abstract][Full Text] [Related]
11. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
12. A methodology to study impactor particle reentrainment and a proposed stage coating for the NGI.
Rissler J; Asking L; Dreyer JK
J Aerosol Med Pulm Drug Deliv; 2009 Dec; 22(4):309-16. PubMed ID: 19415989
[TBL] [Abstract][Full Text] [Related]
13. A Multi-laboratory in Vitro Study to Compare Data from Abbreviated and Pharmacopeial Impactor Measurements for Orally Inhaled Products: a Report of the European Aerosol Group (EPAG).
Nichols SC; Mitchell JP; Sandell D; Andersson PU; Fischer M; Howald M; Pengilley R; Krüger P
AAPS PharmSciTech; 2016 Dec; 17(6):1383-1392. PubMed ID: 26762338
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets.
Berg E; Lamb P; Ali A; Dennis J; Tservistas M; Mitchell J
Pharmeur Sci Notes; 2008 Feb; 2008(1):21-5. PubMed ID: 18430403
[TBL] [Abstract][Full Text] [Related]
15. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
16. Distortion of cascade impactor measured size distribution due to bounce and blow-off.
Esmen NA; Lee TC
Am Ind Hyg Assoc J; 1980 Jun; 41(6):410-9. PubMed ID: 7395754
[TBL] [Abstract][Full Text] [Related]
17. Design, calibration and testing of a parallel stage impactor.
Lee TC; Esmen NA
Am Ind Hyg Assoc J; 1980 Apr; 41(4):240-7. PubMed ID: 7395739
[TBL] [Abstract][Full Text] [Related]
18. A new approach to characterise pharmaceutical aerosols: measurement of aerosol from a single dose aqueous inhaler with an optical particle counter.
Kuhli M; Weiss M; Steckel H
Eur J Pharm Sci; 2010 Jan; 39(1-3):45-52. PubMed ID: 19874891
[TBL] [Abstract][Full Text] [Related]
19. The development of a novel dry powder inhaler.
Zhang X; Ma Y; Zhang L; Zhu J; Jin F
Int J Pharm; 2012 Jul; 431(1-2):45-52. PubMed ID: 22543053
[TBL] [Abstract][Full Text] [Related]
20. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying.
Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P
Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
